Neurology

Verdict for Biogen’s Long-Awaited Alzheimer’s Drug Is Finally Here   The USFDA finally gave approval to eagerly-anticipated Biogen’s Drug Aducanumab for the treatment of Alzheimer’s disease under the accelerated approval pathway. The drug, marketed under the name Aduhelm, is the first that treats an underlying cause of the disease.  Biogen and its collaborator Eisai had abandoned the drug in March 2019 after the drug failed to meet endpoints. However, after a few months, the company again got back in full swing with its drug with a full analysis of  one of the trials, the Phase III EMERGE study, demonstrating that the drug had hit the primary endp...